Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Raj_Kannan
|
| gptkbp:collaboratesWith |
gptkb:AbbVie
|
| gptkbp:country |
gptkb:China
|
| gptkbp:focus |
immuno-oncology
autoimmune diseases |
| gptkbp:foundedYear |
2016
|
| gptkbp:founder |
gptkb:Jingwu_Zang
|
| gptkbp:headquartersLocation |
gptkb:Shanghai,_China
|
| https://www.w3.org/2000/01/rdf-schema#label |
I-Mab Biopharma
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedSince |
2020
|
| gptkbp:notableProduct |
gptkb:felzartamab
gptkb:lemzoparlimab |
| gptkbp:numberOfEmployees |
over 400
|
| gptkbp:regionServed |
global
|
| gptkbp:researchArea |
biologics
monoclonal antibodies |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:IMAB
|
| gptkbp:website |
https://www.i-mabbiopharma.com/
|
| gptkbp:bfsParent |
gptkb:Zhangjiang
|
| gptkbp:bfsLayer |
6
|